FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Oral tablet
Site JP00024
Chiba, Japan
Site JP00023
Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
Time frame: Baseline and week 52 (or the time of last assessment for participants who discontinued earlier)
Change From Baseline to Last Assessment in Treatment Period in Hamilton Depression Scale (HAM-D17)
The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 with lower scores indicating less depressive symptoms.
Time frame: Baseline and week 52 (or the time of last assessment for participants who discontinued earlier)
Change From Baseline to Last Assessment in Treatment Period in Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill).
Time frame: Baseline and week 52 (or the time of last assessment for participants who discontinued earlier)
Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Depression
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill).
Time frame: Baseline and week 52 (or the time of last assessment for participants who discontinued earlier)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Fukuoka, Japan
Site JP00025
Fukuoka, Japan
Site JP00015
Fukushima, Japan
Site JP00029
Fukushima, Japan
Site JP00001
Hokkaido, Japan
Site JP00002
Hokkaido, Japan
Site JP00003
Hokkaido, Japan
Site JP00004
Hokkaido, Japan
Site JP00005
Hokkaido, Japan
...and 22 more locations
Change From Baseline to Last Assessment in Treatment Period in CGI-BP-S: Mania
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill).
Time frame: Baseline and and week 52 (or the time of last assessment for participants who discontinued earlier)
Clinical Global Impression-Bipolar-Change (CGI-BP-C): Overall Bipolar Illness
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Time frame: Week 52 (or the time of last assessment for participants who discontinued earlier)
CGI-BP-C: Depression
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Time frame: Week 52 (or the time of last assessment for participants who discontinued earlier)
CGI-BP-C: Mania
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Time frame: Week 52 (or the time of last assessment for participants who discontinued earlier)
Number of Participants With Adverse Events
An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, re quire d or prolonged hospitalization or was considered medically important.
Time frame: From first dose of study drug up to week 52 (52 weeks)